RCUS
USDArcus Biosciences Inc. Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$19.700
उच्च
$20.500
कम
$19.691
मात्रा
0.41M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
2.4B
उद्योग
जैव प्रौद्योगिकी
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
1.18M
एक्सचेंज
NYQ
मुद्रा
USD
52-सप्ताह रेंज
संबंधित समाचार
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences with a Neutral and raises the price target from $14 to $16.
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $54 to $56.
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences with a Buy and raises the price target from $24 to $28.
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $47 to $54.
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing
संबंधित स्टॉक
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।